ArticleBMC ophthalmology2026
Combined anti-VEGF approach in neovascular glaucoma: clinical outcomes of intracameral and intravitreal bevacizumab administration.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate short-term clinical outcomes of combined intracameral and intravitreal bevacizumab administration in patients with neovascular glaucoma (NVG), with emphasis on intraocular pressure (IOP), best-corrected visual acuity (BCVA), and regression of anterior segment neovascularization.
methodsThis retrospective study included 90 eyes of 81 patients with NVG who received simultaneous intracameral and intravitreal bevacizumab injections between January 2020 and January 2025. BCVA, IOP, and rubeosis iridis were assessed at baseline and at 1 week, 1 month, and 3 months post-treatment. Additional interventions, including panretinal photocoagulation (PRP), repeat anti-VEGF injections, and glaucoma surgeries, were documented.
resultsThe mean patient age was 65.47 ± 10.06 years, and 69.2% were male. Diabetic retinopathy (66.7%) and central retinal vein occlusion (26.7%) were the most common underlying etiologies. Median BCVA demonstrated modest improvement, with statistically significant gains at 1 and 3 months compared with baseline (p < 0.01). Mean IOP decreased significantly from 32.9 ± 12.1 mmHg at baseline to 21.4 ± 10.1 mmHg at 3 months (p < 0.001). Regression of rubeosis iridis was observed in 71.5% of eyes by month 3. PRP was performed in 66.7% of cases, while trabeculectomy or cyclocryotherapy was required in 23.3% of eyes. Hyphema occurred in 3.3% of patients, with no other serious complications.
conclusionsCombined intracameral and intravitreal bevacizumab appears to be a safe and effective short-term strategy for NVG management, providing significant IOP reduction and regression of anterior segment neovascularization. Although visual improvement was limited, this dual-route anti-VEGF approach may serve as an effective bridge therapy facilitating subsequent definitive retinal or glaucoma interventions, particularly in advanced cases with corneal edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.